BioLineRx (BLRX) EBITDA (2011 - 2025)

BioLineRx's EBITDA history runs 14 years deep, the most recent figure standing at -$3.4 million for Q4 2025.

• On a quarterly basis, EBITDA rose 23.5% year-over-year to -$3.4 million in Q4 2025; TTM through Dec 2025 was -$10.3 million, a 49.59% increase from a year earlier, with the FY2025 full-year figure at -$10.3 million, up 49.59% from the prior year.
• EBITDA declined to -$3.4 million in Q4 2025 per BLRX's latest filing, from -$2.2 million in the prior quarter.
• Across five years, EBITDA topped out at -$2.2 million in Q3 2025 and bottomed at -$18.6 million in Q4 2023.
• The 5-year median for EBITDA is -$6.1 million (2021), against an average of -$6.7 million.
• Across the five-year window, EBITDA sank 121.08% in 2023 and soared 76.16% in 2024, its largest moves.
• Year by year, EBITDA stood at -$6.6 million in 2021, then fell by 27.28% to -$8.4 million in 2022, then sank by 121.08% to -$18.6 million in 2023, then surged by 76.16% to -$4.4 million in 2024, then gained by 23.5% to -$3.4 million in 2025.
• Per Business Quant, the three latest BLRX EBITDA figures stand at -$3.4 million (Q4 2025), -$2.2 million (Q3 2025), and -$2.3 million (Q2 2025).